[EN] NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS [FR] NOUVEAUX COMPOSES D'OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT D'ARYTHMIES CARDIAQUES
Exploiting polarity and chirality to probe the Hsp90 C-terminus
作者:Leah K. Forsberg、Rachel E. Davis、Virangika K. Wimalasena、Brian S.J. Blagg
DOI:10.1016/j.bmc.2018.04.028
日期:2018.7
an attractive therapeutic approach for the treatment of cancer. Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically complex noviose sugar that has limited the generation of structure-activity relationships for this region of the molecule. The work described herein utilizes various ring systems as noviose surrogates to explore the size and nature of the surrounding binding
Hsp90 C 末端的抑制是治疗癌症的一种有吸引力的治疗方法。新生霉素是第一个被鉴定的 Hsp90 C 末端抑制剂,含有一种合成复杂的新生糖,它限制了该分子区域结构-活性关系的生成。本文描述的工作利用各种环系统作为新手替代物来探索周围结合袋的大小和性质。
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
申请人:Hoffmann-La Roche Inc.
公开号:US20150210682A1
公开(公告)日:2015-07-30
The invention provides novel compounds having the general formula:
wherein R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as described herein, compositions including the compounds and methods of using the compounds.
[EN] NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES DIHYDROQUINOLIZINONES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
申请人:HOFFMANN LA ROCHE
公开号:WO2015113990A1
公开(公告)日:2015-08-06
The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.
A synthetic method is presented for S−N bond formation starting from cheap and affordable materials. We show that (un)substituted N-protected cyclic eight-membered C2-symmetric sulfenamides have been prepared in a few steps using this procedure. The syntheticutility of these ambipolar derivatives was demonstrated in a variety of synthetic transformations affording different S,N-heterocyles of pharmaceutical
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.